Business Context and Reporting Period
BioNexus Gene Lab Corp. (BGLC), a Wyoming corporation listed on The Nasdaq Stock Market, filed this Form 8-K on February 11, 2025. The report details corporate governance actions taken on February 10 and 11, 2025, regarding the creation and issuance of a new class of preferred stock.
Key Financial Metrics
This filing is a current report regarding corporate structure and does not contain financial performance data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Creation of Series Z Preferred Stock: The Board of Directors approved the creation of one (1) share of Series Z Convertible Preferred Stock.
- Issuance: The single share was issued to Muhammad Azrul bin Abdul Hamid, a member of the Board of Directors and the Audit Committee.
- Voting Rights: The Series Z share carries 5,000,000,000 votes. These votes are restricted exclusively to a proposed Reverse Stock Split to be voted on during calendar year 2025.
- Voting Mechanism: The Series Z share will automatically vote in the same proportion as the Common Stock votes on the Reverse Stock Split proposal, effectively mirroring the common shareholders' decision.
- Amendment to Articles: Articles of Amendment were filed with the Wyoming Secretary of State on February 11, 2025, to authorize this stock class.
Outlook, Risks, and Management Commentary
Purpose: Management states the purpose of the Series Z Preferred Stock is to increase the likelihood of procuring the votes necessary to effectuate the Reverse Stock Split Proposal. The stock is designed to increase the aggregate voting power without altering the percentage of votes cast for or against the proposal.
Compliance: The Company believes this action complies with Nasdaq Rule 5640, referencing Nasdaq Staff Interpretation Letter 1841.
Cancellation Terms: The Series Z share may be cancelled automatically upon shareholder approval of the Reverse Stock Split or at the sole discretion of the Board of Directors.
Risks: The filing does not explicitly list new risks, though the issuance of unregistered securities and the modification of shareholder rights are noted as material events.
Investor Verification Checklist
- Verify the terms of the Reverse Stock Split proposal in the recent Preliminary Proxy Statement.
- Confirm the voting record of the Special Shareholders' Meeting scheduled for 2025.
- Review the Articles of Amendment (Exhibit 3.6) for full legal details on the Series Z Preferred Stock.
- Monitor for the automatic cancellation of the Series Z share upon the outcome of the Reverse Stock Split vote.